Tags

Type your tag names separated by a space and hit enter

Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.
Scand J Infect Dis. 2004; 36(4):254-8.SJ

Abstract

A total of 839 clinical isolates of Gram-positive cocci from Norway including Staphylococcus aureus (n = 214), coagulase negative Staphylococcus spp. (n = 100), Streptococcus pyogenes (n = 99), Streptococcus agalactiae (n = 80), Streptococcus pneumoniae (n = 127), Streptococcus spp. viridans group (n = 70), Enterococcus faecalis (n = 75), and Enterococcus faecium (n = 74), were tested by E-test for susceptibility to a range of antimicrobials including the novel antibiotics quinupristin-dalfopristin and linezolid. Subgroups of oxacillin resistant S. aureus and coagulase negative Staphylococcus spp., penicillin non-susceptible S. pneumoniae and vancomycin resistant Enterococcus spp. were specifically included as they are the intended targets for these new drugs. All isolates were susceptible to linezolid (MIC5o and MIC9o 0.25-2.0 mg/l, MIC range 0.12-2 mg/l). Staphylococcal and streptococcal isolates were also susceptible to quinupristin-dalfopristin except for some intermediately susceptible viridans group isolates (MIC54, and MIC90 0.25-2 mg/l, MIC range 0.125-2 mg/l). Enterococcus faecium (MIC90 = 4.0 mg/l) and Enterococcus faecalis (MIC50 = 8.0 mg/l, MIC90 > or = 32 mg/l) were less susceptible to this substance. There was no linkage between reduced susceptibility to linezolid or quinupristin-dalfopristin and resistance to other classes of antimicrobials. The study demonstrated a high prevalence of in vitro susceptibility to linezolid and quinupristin-dalfopristin, which is necessary for their use in the treatment of infections with resistant Gram-positive pathogens. The results were used to evaluate the appropriateness of breakpoints and to define a baseline for monitoring possible future emergence of resistance to quinupristin-dalfopristin and linezolid in Norway.

Authors+Show Affiliations

Department of Microbiology, University of Tromsø, University Hospital of North Norway, Tromsø, Norway. gunnar.skov.simonsen@unn.noNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15198180

Citation

Simonsen, Gunnar S., et al. "Susceptibility to Quinupristin-dalfopristin and Linezolid in 839 Clinical Isolates of Gram-positive Cocci From Norway." Scandinavian Journal of Infectious Diseases, vol. 36, no. 4, 2004, pp. 254-8.
Simonsen GS, Bergh K, Bevanger L, et al. Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway. Scand J Infect Dis. 2004;36(4):254-8.
Simonsen, G. S., Bergh, K., Bevanger, L., Digranes, A., Gaustad, P., Melby, K. K., & Høiby, E. A. (2004). Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway. Scandinavian Journal of Infectious Diseases, 36(4), 254-8.
Simonsen GS, et al. Susceptibility to Quinupristin-dalfopristin and Linezolid in 839 Clinical Isolates of Gram-positive Cocci From Norway. Scand J Infect Dis. 2004;36(4):254-8. PubMed PMID: 15198180.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway. AU - Simonsen,Gunnar S, AU - Bergh,Kåre, AU - Bevanger,Lars, AU - Digranes,Asbjørn, AU - Gaustad,Peter, AU - Melby,Kjetil K, AU - Høiby,E Arne, PY - 2004/6/17/pubmed PY - 2004/7/28/medline PY - 2004/6/17/entrez SP - 254 EP - 8 JF - Scandinavian journal of infectious diseases JO - Scand J Infect Dis VL - 36 IS - 4 N2 - A total of 839 clinical isolates of Gram-positive cocci from Norway including Staphylococcus aureus (n = 214), coagulase negative Staphylococcus spp. (n = 100), Streptococcus pyogenes (n = 99), Streptococcus agalactiae (n = 80), Streptococcus pneumoniae (n = 127), Streptococcus spp. viridans group (n = 70), Enterococcus faecalis (n = 75), and Enterococcus faecium (n = 74), were tested by E-test for susceptibility to a range of antimicrobials including the novel antibiotics quinupristin-dalfopristin and linezolid. Subgroups of oxacillin resistant S. aureus and coagulase negative Staphylococcus spp., penicillin non-susceptible S. pneumoniae and vancomycin resistant Enterococcus spp. were specifically included as they are the intended targets for these new drugs. All isolates were susceptible to linezolid (MIC5o and MIC9o 0.25-2.0 mg/l, MIC range 0.12-2 mg/l). Staphylococcal and streptococcal isolates were also susceptible to quinupristin-dalfopristin except for some intermediately susceptible viridans group isolates (MIC54, and MIC90 0.25-2 mg/l, MIC range 0.125-2 mg/l). Enterococcus faecium (MIC90 = 4.0 mg/l) and Enterococcus faecalis (MIC50 = 8.0 mg/l, MIC90 > or = 32 mg/l) were less susceptible to this substance. There was no linkage between reduced susceptibility to linezolid or quinupristin-dalfopristin and resistance to other classes of antimicrobials. The study demonstrated a high prevalence of in vitro susceptibility to linezolid and quinupristin-dalfopristin, which is necessary for their use in the treatment of infections with resistant Gram-positive pathogens. The results were used to evaluate the appropriateness of breakpoints and to define a baseline for monitoring possible future emergence of resistance to quinupristin-dalfopristin and linezolid in Norway. SN - 0036-5548 UR - https://www.unboundmedicine.com/medline/citation/15198180/Susceptibility_to_quinupristin_dalfopristin_and_linezolid_in_839_clinical_isolates_of_Gram_positive_cocci_from_Norway_ L2 - https://www.tandfonline.com/doi/full/10.1080/00365540410019570 DB - PRIME DP - Unbound Medicine ER -